Ferric Carboxymaltose [Ferinject]
HER2 Positive Breast Cancer
GBG Forschungs GmbHPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the HER2 Positive Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinorelbine Jazz Pharmaceuticals | Phase 3 | BBB |
Epirubicin Shanghai JMT-Bio Inc. | Phase 3 | BB |
Trastuzumab Sc Peking University Cancer Hospital & Institute | Phase 3 | BB |
FERRIC CATION GBG Forschungs GmbH | Phase 3 | B |
Inno-206 GBG Forschungs GmbH | Phase 3 | B |
View all 14 →
Same molecule, other indications
Ferric Carboxymaltose [Ferinject] is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →